# SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

> **NCT07129187** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chuan Wang** · enrollment: 30 (estimated)

## Conditions studied

- Early Breast Cancer
- HER2 + Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer

## Interventions

- **DRUG:** SHR-A1811

## Key facts

- **NCT ID:** NCT07129187
- **Lead sponsor:** Chuan Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-10
- **Final completion:** 2030-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07129187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07129187, "SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07129187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*